PGY-2 @UTSWInternalMed | Research Collaborator @MayoClinicGIHep | MD @USFQ_Ecuador 🇪🇨 | Aspiring GI | #COYG 🔴 | ⚽️ 🏓🧉🤿
Joined July 2012
- Tweets 547
- Following 710
- Followers 756
- Likes 2,108
29 Photos and videos
Pinned Tweet
15 Mar 2024
Beyond thrilled to have matched at my dream program! @UTSWInternalMed @UTSWIMchief
Forever grateful for the support from my family, soon-to-be wife, friends, and exceptional mentors @dr_aac @Dr_RADillingham @Pablo_delaC @MDanielaHurtado
Dallas, here we go! 🚀 #Match2024
21
12
311
17,228
Diego Anazco, MD retweeted
In people with a suboptimal clinical response after MBS, semaglutide results in substantial and clinically significant body weight reduction along with improvement in metabolic parameters and quality of life, compared to placebo @NatureMedicine nature.com/articles/s41591-0…
1
6
20
4,563
May 13
Don’t miss this great opportunity! Excited for the upcoming “Coffee with the Expert” session with @JaimeAlmandoz
If you’re interested in obesity medicine, research, or academic mentorship, this is a session you won’t want to miss! ☕️
@ObesitySociety @UTSWInternalMed
☕ Join @JaimeAlmandoz, MD, MBA, for Coffee with the Expert on May 28, 2-3 pm ET! 🔗 Register: ow.ly/GXiA50YYvBP #ObesityScience #ObesityMedicine #Mentorship #EarlyCareer #TheObesitySociety @UTSWMedCenter
1
8
885
Diego Anazco, MD retweeted
Another excellent #DDW2026
Great connecting with colleagues, collaborators & industry partners on advancing liver & metabolic health, expanding clinical trial access, & improving patient care
Thanks to all who took the time to meet with @TexasLiverCare & @EvidentisHQ in Chicago
1
6
16
753
Had a blast at #DDW2026 in Chicago! Great reconnecting with friends and mentors, and meeting so many inspiring people. Grateful for the support of amazing mentors and my residency program 🙌
@UTSWIMchief @UTSWInternalMed @UTSWGI @dr_aac @JaimeAlmandoz @DDWMeeting @AmerGastroAssn
20
421
Diego Anazco, MD retweeted
May 1
Proud to showcase the incredible work from @UTSWGI at @DDWMeeting! 🔥
📍 50 lectures & posters 🎤 📊
📍 Faculty, fellows, and trainees leading innovation in GI 🧠
Join us in Chicago and follow along as we share advances in hepatology, IBD, GI oncology, and beyond 💫
1
4
46
1,931
Diego Anazco, MD retweeted
Apr 16
GLP-1 medicine improves liver health independent of weight loss, according to a new study #UofT ➡️ uoft.me/cjP
ALT Daniel Drucker, a senior investigator at Sinai Health and a University Professor in U of T’s Temerty Faculty of Medicine, and postdoctoral researcher Maria Gonzalez-Rellan found that semaglutide acts directly on the liver to reduce inflammation and scarring, and improve organ function (supplied image)
22
104
7,034
Diego Anazco, MD retweeted
Proud to share our latest @AlcHepNet work in @ACERjournal
doi.org/10.1111/acer.70263
Among 518 survivors of alcohol-associated hepatitis, >20% returned to drinking by 3 months
AH care must integrate early, proactive AUD treatment
Supports @NIAAAnews ITAALD study rationale
1
21
46
2,776
Diego Anazco, MD retweeted
Phosphatidylethanol (PEth) predicts hepatic decompensation independently of NITs in those at risk of alcohol-related liver disease. Repeated PEth sustains prognostic utility.
🔗 ow.ly/3Uoa50YASne
@NikolajTorp @AleksanderKrag @IsraelsenMads @MajaThiele
14
30
2,135
Diego Anazco, MD retweeted
Mar 25
As the role of #GLP1 therapies in #MASLD continues to grow, clinicians need clear guidance.
A new Practice Guidance update in @HEP_Journal provides evidence-based recommendations on using semaglutide therapy for MASH, including patient selection, comorbidity management, and monitoring strategies.
📗 View the update: bit.ly/4s4QM6A
1
28
64
3,954
Diego Anazco, MD retweeted
So lucky to have worked with my good friend @gioroldanc
This is great work, so proud of you
Clostridioides difficile Infection Among Hospitalized Patients With Cancer jamanetwork.com/journals/jam…
1
5
793
The IARC Working Group summarizes guidance on 𝘏. 𝘱𝘺𝘭𝘰𝘳𝘪 screen-and-treat programs for gastric cancer prevention and concludes that prevention is the most effective strategy amid a rising global burden. Learn more: nejm.org/doi/full/10.1056/NE…
ALT A map showing age-standardized incidence rates of gastric cancer among men and women in 2022 according to country.
2
36
99
15,307
Diego Anazco, MD retweeted
#LFNpearls By: @sarachapinMD
⭐️ Immunosuppression after liver transplant: simple in concept, complex in practice.
⭐️ How do you balance rejection, renal function, and malignancy risk?
🔗 aasld.org/liver-fellow-netwo…
1
7
21
3,732
Diego Anazco, MD retweeted
The results are in! Join us in congratulating and welcoming our new residents, who will be joining us in July. @UTSWIMchief #UTSWmatch #Match2026
23
191
52,642
Diego Anazco, MD retweeted
Join Brendon Neuen, MBBS (Hons), MSc (Oxon), PhD, FRACP, FASN, for TOS Coffee with the Expert on March 26, 2026, 4:30 p.m. ET. 🔗 ow.ly/pTvM50Yvfxp #ObesityResearch #CardiovascularHealth #EarlyCareerResearchers
1
3
275
Diego Anazco, MD retweeted
Great start to our St. Patrick’s Day Liver & Metabolic Health Fair ☘️
20 community members already screened and we’re just getting started, 3 hours still to go.
Come by Texas Liver Care in Fort Worth to check your liver and metabolic health! Along with plenty of activities for kids!
8
12
745
Diego Anazco, MD retweeted
Among adults with overweight or obesity, <25% remained on a #GLP1RA at 12 months. Switching agents was common and linked to higher persistence and adherence than remaining on one agent.
ja.ma/40oLmqU
ALT Sankey diagram showing medication switches. Semaglutide (Wegovy) 45 098 (35.5%), Semaglutide (Ozempic) 34 828 (27.4%), Liraglutide (Saxenda) 26 384 (20.8%), Tirzepatide 9866 (7.8%), Semaglutide (Rybelsus) 4619 (3.6%), Dulaglutide 4438 (3.5%).
1
2
19
5,559
Mar 10
🚨Take a look at our team’s new work in @JAMANetwork. Switching GLP-1 RAs should not be seen as a failure but rather as an adaptation that can facilitate persistence and adherence! jamanetwork.com/journals/jam…
@UTSWInternalMed @JaimeAlmandoz @UTSWIMchief @ObesitySociety @WorldObesity
1
4
257